• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, June 5

Wockhardt has signed an in-licensing agreement with the UK-based derma company LSI to market Vitix, a patented product for the treatment of pigmentation disorder vitiligo.

Vitiligo is a skin disorder where the patient develops white patches caused by localised loss of pigmentation and the problem affects 1-2 per cent of global population.

Vitix is a gel for topical application and will be manufactured by Wockhardt in India from active pharmaceutical ingredients (API) imported from LSI, a note from Wockhardt said.

Vitix is expected to be launched in the last quarter of 2006. The product is already marketed in Europe, North America, South-East Asia and Africa.

In-licensing Vitix would strengthen Wockhardt's dermatology portfolio and that includes the Nadoxin range, a quinolone antibiotic for topical use.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BHEL gets Gammon order

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line